January 21, 2011

JEVTANA® (cabazitaxel) for Prostate Cancer Recommended for Approval in the European Union

- Therapy provides significant survival benefit in second-line metastatic hormonerefractory prostate cancer in combination with prednisone or prednisolone -

 

JEVTANA® (cabazitaxel) for Prostate Cancer Recommended for Approval in the European Union
- Therapy provides significant survival benefit in second-line metastatic hormonerefractory prostate cancer in combination with prednisone or prednisolone -

Paris, France – January 21, 2011 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for JEVTANA® (Cabazitaxel – 60mg concentrate and solvent for solution for infusion) in combination with prednisone or prednisolone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing treatment regimen.